(Q27851620)

13 November 2016

title

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer (English)

1 reference

PubMed publication ID

13 November 2016

1 reference

1 reference

15

0 references

Charles Ginther

13

Charles Ginther

0 references

Judy Dering

6

Judy Dering

0 references

Boris Winterhoff

Boris Winterhoff

2

0 references

Meenal Chalukya

8

Meenal Chalukya

0 references

Kanthinh Manivong

5

Kanthinh Manivong

0 references

Siân Jones

14

Siân Jones

0 references

Lynn C. Hartmann

20

Lynn C Hartmann

0 references

Kimberly R Kalli

11

Kimberly R Kalli

0 references

Gottfried E Konecny

1

Gottfried E Konecny

0 references

William A Cliby

17

William A Cliby

0 references

Dennis Slamon

21

Dennis J Slamon

0 references

author name string

Teodora Kolarova

3

0 references

Jingwei Qi

4

0 references

Guorong Yang

7

0 references

He-Jing Wang

9

0 references

Lee Anderson

10

0 references

Richard S Finn

12

0 references

Darren Riehle

16

0 references

Sophia Randolph

18

0 references

Maria Koehler

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

19

0 references

language of work or name

English

0 references

publication date

15 March 2011

0 references

published in

Clinical Cancer Research

0 references

volume

17

0 references

issue

6

0 references

page(s)

1591-602

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

20 March 2017

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Identification of G1 kinase activity for cdk6, a novel cyclin D partner

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

The consensus coding sequences of human breast and colorectal cancers

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Tumor suppression by Ink4a-Arf: progress and puzzles

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

The Rb/E2F pathway: expanding roles and emerging paradigms

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Inhibition of ras-induced proliferation and cellular transformation by p16INK4.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4598646

Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus

27 November 2018

1 reference

12 December 2020

Loss of heterozygosity at the RB-1 locus and pRB immunostaining in epithelial ovarian tumors: a molecular, immunohistochemical, and clinicopathologic study

1 reference

12 December 2020

1 reference

12 December 2020

Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer

1 reference

12 December 2020

10.1158/1078-0432.CCR-10-2307

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

21278246

1 reference